Vanguard Fiduciary Trust
TTRX

Vanguard Fiduciary Trust’s Turn Therapeutics TTRX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.1K Hold
12,480
– – ﹤0.01% 3755
2026
Q1 		$39.9K Buy
+12,480
New +$48.6K ﹤0.01% 3866

Other funds holding TTRX

SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
DI
DDFG Inc Thousand Oaks, California $504M AUM 18.61% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BA
Bridgewater Advisors New York $1.83B AUM 22.9% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $1.07B AUM 26.86% 1-Year Est. Return

Vanguard Fiduciary Trust's TTRX Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Turn Therapeutics (TTRX) position steady in Q2 2026 at 12,480 shares worth $91.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3755.

Vanguard Fiduciary Trust first reported a position in TTRX in Q1 2026 and has held it in 2 quarters since. 29 funds tracked by Wall St. Rank hold TTRX as of Q2 2026.

  • Vanguard Fiduciary Trust held 12,480 shares of Turn Therapeutics worth $91.1K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Turn Therapeutics share count unchanged in Q2 2026.
  • Turn Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3755 holding.
  • Vanguard Fiduciary Trust first reported a position in Turn Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 29 funds tracked by Wall St. Rank held Turn Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.